LAUSR

Previous studies have shown that serum anti-p53 antibodies (s-p53-Abs) can be detected independently from conventional tumor markers and may be used in diagnosis and screening, and to monitor treatment response and tumor recurrence, in patients with esophageal and colorectal cancer. The diagnostic sensitivity of conventional tumor markers may be enhanced with the addition of s-p53-Abs, suggesting a promising role for s-p53-Abs. In the majority of previous reports, anti-p53 antibody detection was performed using the quantitative p53-Abs ELISA Kit II (MESACUP anti-p53 Test; MBL, Nagoya, Japan). Validation of this assay system was performed to evaluate the diagnostic values of s-p53-Abs in a large spectrum of patients with various malignant tumors. Although the detection of s-p53-Abs is clinically useful, ELISAs are time consuming, involve multiple steps, and are only semiquantitative.